Comparative Effects of Alternative Nostril Breathing Versus Buteyko Breathing on Control Pause, Dyspnea and Pulmonary Function in Patients With Bronchial Asthma
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Control Pause
研究概览
简要总结
Bronchial asthma is a chronic inflmmatory airway disease characterized by recurrent episodes of dyspnea, wheezing, and airflow limitation.
Dysfunctional breathing pattern and chronic hyperventilation
详细描述
Bronchial asthma is a chronic inflammatory airway disease in which there are recurrent episodes shortness of breath, wheezing,and limitation in airflow.
Chronic hyperventilation and dysfunctional breathing pattern and commonly contribute to symptom severity and poor asthma control.This study aims to compare the effects of Alternate Nostril Breathing and Buteyko Breathing Technique on control pause, dyspnea, pulmonary function, and asthma control in patients with bronchial asthma.This study aims to compare the effects of Alternate Nostril Breathing and Buteyko Breathing Technique on control pause, dyspnea, pulmonary function, and asthma control in patients with bronchial asthma.This study aims to compare the effects of Alternate Nostril Breathing and Buteyko Breathing Technique on control pause, dyspnea, pulmonary function, and asthma control in patients with bronchial asthma.A total of 40 patients with mild to moderate persistent bronchial asthma will be recruited and randomly allocated into two groups. Group A will receive Alternate Nostril Breathing, while Group B will receive the Buteyko Breathing Technique, along with standard pharmacological management.
The intervention will be conducted over a period of four weeks, with two supervised sessions per week and additional home-based sessions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18-45 years
- •Both genders (male and female)
- •Grade 1-3 on mMRC scale of dyspnea
- •Asthma severity classes- intermediate,mild persistent and moderate persistent asthma (acc. to NAEPP National Asthma Education and Prevention Program guidlines 2020)
排除标准
- •Patients having acute exerbation of COPD/status asthmaticus
- •Patients diagnosed with acute infection
- •Patients unable to follow command and instructions
- •Asthma patients with >40sec control pause duration
研究组 & 干预措施
Alternate Nostril Breathing
Patients in this group will receive Alternate Nostril Breathing (ANB) along with standard pharmacological management as prescribed by the pulmonologist.
The breathing intervention will be performed for a duration of 4 weeks. Two sessions per week will be supervised by a physiotherapist, and five sessions per week will be performed at home. Each session will last 10-15 minutes, following a structured ANB protocol involving slow nasal inhalation and exhalation with brief breath holds.
A home exercise diary will be provided to ensure adherence and follow-up of breathing exercises performed at home.
干预措施: Alternative Nostril Breathing Technique along with standard pharmacological management (Other)
Buteyko Breathing
Patients in this group will receive the Buteyko Breathing Technique (BBT) along with standard pharmacological management as prescribed by the pulmonologist. The intervention will be administered over a period of 4 weeks. Two sessions per week will be supervised by a physiotherapist, while five sessions per week will be carried out at home. Each session will last 10-15 minutes and will include controlled nasal breathing, relaxed exhalation, and breath holding (control pause) until the first sensation of air hunger.
A home diary will be provided to monitor compliance and ensure regular performance of breathing exercises at home.
干预措施: Buteyko breathing along with pharmacological management (Other)
结局指标
主要结局
Control Pause
时间窗: 04 weeks
Evaluation will be performed using the Control Pause test, defined as the duration (in seconds) a participant can comfortably hold their breath after a normal exhalation. The measurement will be recorded using a stopwatch. Participants will be assessed in a seated position following normal tidal breathing, and breath-hold will be initiated after a normal exhalation without prior deep inspiration. The Control Pause duration ranges from 0 seconds to the maximum voluntary breath-hold time. Higher values indicate better breath control and improved respiratory function, whereas lower values indicate poorer respiratory status.
Dyspnea
时间窗: 04 weeks
Evaluation will be performed using the Dyspnea-12 Questionnaire (D-12), a validated patient-reported outcome measure consisting of 12 items assessing both physical and affective components of breathlessness. The total score ranges from 0 to 36, with each item scored from 0 (none) to 3 (severe). Higher scores indicate greater severity of dyspnea and worse symptom burden.
Pulmonary Function Test
时间窗: 04 weeks
Evaluation will be performed using spirometry, conducted according to standard guidelines. The primary parameters assessed will include Forced Expiratory Volume in 1 second (FEV₁), Forced Vital Capacity (FVC), and FEV₁/FVC ratio. Values will be recorded in liters (L) and as percentage of predicted values (%) based on age, sex, height, and ethnicity. Higher values of FEV₁ and FVC indicate better pulmonary function, while a higher FEV₁/FVC ratio indicates reduced airflow obstruction and improved respiratory status.
Asthma Control
时间窗: 04 weeks
Evaluation will be performed using the Asthma Control Test (ACT), a validated patient-reported questionnaire consisting of 5 items assessing asthma symptoms and control over the past 4 weeks. Each item is scored on a 5-point scale (1-5), with a total score ranging from 5 to 25. Higher scores indicate better asthma control, while lower scores indicate poorer control. A score of ≥20 suggests well-controlled asthma, whereas scores \<20 indicate partially controlled or poorly controlled asthma.
次要结局
未报告次要终点